18F-PI-2620 is a special type of imaging agent used in a medical scan called a PET scan. This agent helps doctors see certain proteins in the brain that are linked to Alzheimer’s disease, especially in people with Down syndrome. The purpose of using this agent in the study is to find out how well it can detect these proteins over time and to ensure it is safe for both healthy individuals and those with Down syndrome. By using this agent, doctors hope to better understand the changes happening in the brain and improve the diagnosis and monitoring of Alzheimer’s disease in these patients.

Alzheimer disease – Alzheimer disease is a progressive neurological disorder that leads to the degeneration of brain cells. It primarily affects memory, thinking, and behavior. The disease progresses through stages, starting with mild memory loss and confusion. As it advances, individuals may experience difficulty in recognizing familiar people, performing daily tasks, and communicating. In later stages, individuals may lose the ability to respond to their environment and require full-time care. The progression of symptoms varies among individuals.

Down Syndrome – Down Syndrome is a genetic disorder caused by the presence of an extra chromosome 21. It is characterized by developmental delays and physical features such as a flat facial profile and upward slanting eyes. Individuals with Down Syndrome may experience mild to moderate intellectual disability. The condition can also be associated with various health issues, including heart defects and thyroid problems. Developmental milestones are typically reached at a slower pace compared to peers. The degree of progression and associated health challenges can vary widely among individuals.